Photodynamic therapy in subfoveal choroidal neovascularisation

Medical Laser Application

Volumn 17, Issue 4, 2002, Pages 331-340

  Berger, Lisa ^a   Stoffelns, Bernhard M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Age related macular degeneration; Pathologic myopia; Photodynamic therapy; Subfoveal choroidal neovascularisation; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTICLE; BACKACHE; CASE REPORT; CLINICAL FEATURE; DRUG HALF LIFE; FEMALE; HUMAN; INJECTION SITE; MALE; MYOPIA; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SOMATOSENSORY CORTEX; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT;

EID: 0036959697     PISSN: 16151615     EISSN: None     Source Type: Journal    
DOI: 10.1078/1615-1615-00078     Document Type: Article

References (39)

1. ALLISON B, PRITCHARD P, LEVY J: Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivate. Br J Cancer 69: 833-839 (1994)
2. AVELINE B, HASAN T, REDMOND R: Photophysical and photo- sensitising properties of benzoporphyrin derivate monoacid ring A (BPD-MA). Photochem Photobiol 59: 328-335 (1994)
3. AVILA M, et al.: Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91: 1573-1581 (1984)
4. BIRD A, BRESSLER N, BRESSLER S: An international classification and grading system for age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367-374 (1995)
5. BRESSLER N, BRESSLER S, FINE S: Age-related macular-degeneration. Surv Ophthalmol 32: 375-413 (1988)
6. COHEN S, et al.: Etiology of choroidal neovascularization in young patients. Ophthalmology 103: 1241-1244 (1996)
7. DOUGHERTY T, GOMER C, HENDERSON B: Photodynamic therapy. J Natl Cancer Inst 90: 889-905 (1998)
8. FOGELMAN A, BERLINER J, LENTEN BV: Lipoprotein receptors and endothelial cells. Sem Thromb Hemost 14: 206-209 (1988)
9. FREUND, K, YANNUZZI L, SORENSON J: Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 115: 786-791 (1993)
10. GAFFNEY J, WEST D, ARNOLD A: Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells. J Cell Sci 79: 317-325 (1985)
11. GASS J: Pathogenesis of disciform detachment of the neuroepithelium III. Senile disciform macular degeneration. Am J Ophthalmol 63: 617-664 (1967)
12. GREEN W, ENGER C: Ag-related macular degeneration histopathologic studies. The 1992 Lorenz E Zimmerman Lecture. Ophthalmology 100: 1519-1535 (1977)
13. HASAN T, PARRISH J: Photodynamic therapy of cancer, in Cancer Medicine, HOLLAND J, Editor. Wiliams & Wilkins: Baltimore. 739-751 (1997)
14. HENDERSON B, DOUGHERTY T: How does photodynamic therapy work? Photochem Photobiol 55: 145-157 (1992)
15. HOTCHKISS M, FINE S: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 91: 177-183 (1981)
16. HUSSAIN D, MILLER J: Photodynamic therapy of exudative age-related macular degeneration. Sem Ophthalmol 12: 14-25 (1997)
17. LEVY J, CHAN A, STRONG H: The clinical status of benzoporphyrin derivative. SPIE 2625: 86-95 (1996)
18. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109: 1220-1231 (1991)
19. Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 111: 1200-1209 (1993)
20. Macular Photocoagulation Study Group: Laser Photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 109: 1109-1114 (1994)
21. Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115: 741-747 (1997)
22. MANYAK M, RUSSO A, SMITH P: Photodynamic therapy. J Clin Oncol 6: 380-391 (1988)
23. MILLER H, MILLER B: Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 111: 855-860 (1993)
24. RICHTER A, CERRUTI-SOLA S, STERNBERG E: Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 5: 231-244 (1990)
25. RICHTER A, et al.: Liposomal delivery of a photosensitizer benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse model. Photochem Photobiol 57: 1000-1006 (1993)
26. RICHTER A, YIP S, MEADOWS H: Photosensitising potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. J Clin Laser Med Surg 14: 335-341 (1996)
27. RICHTER A, YIP S, WATERFIELD E: Mouse skin photosensitization with benzoporphyrin derivatives and Photofrin: macroscopic and microscopic evaluation. Photochem Photobiol 53: 281-286 (1991)
28. SCHMIDT-ERFURTH U, BAUMANN W, GRAGOUDAS E: Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101: 89-99 (1994)
29. SCHMIDT-ERFURTH U, BIRNGRUBER R, HASAN T: Photodynamic Therapy in ocular vascular disease. Laser Physics 8: 191-198 (1998)
30. SCHMIDT-ERFURTH U, HASAN T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45: 195-214 (2000)
31. SCHMIDT-ERFURTH U, et al.: In vivo uptake of liposomal benzoporphyrin derivate and photothrombosis in experimental corneal neovascularization. Laser Surg Med 17: 178-188 (1995)
32. SCHMIDT-ERFURTH U, MILLER J, SICKENBERG M: Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236: 365-374 (1998)
33. SCHMIDT-ERFURTH U, MILLER J, SICKENBERG M: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117: 1177-1187 (1999)
34. SICKENBERG M, SCHMIDT-ERFURTH U, MILLER J: A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 118: 327-336 (2000)
35. SOUBRANE G, BRESSLER N: Treatment of subfoveal choroidal neovascularisation in age-related macular degeneration: focus on application of verteporfin photodynamic therapy. Br J Ophthalmol 85: 483-495 (2001)
36. THYLEFORS B, et al.: Global data on blindness. Bull World Health Organ 73: 115-121 (1995)
37. Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One year results of 2 randomized clinical trials - TAP Report 1. Arch-Ophthalmol 117: 1329-1345 (1999)
38. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 119: 198-207 (2001)
39. Verteporfin in Photodynamic Therapy (VIP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-Year results of a randomized clinical trial - VIP Report #1. Ophthalmology 108: 841-853 (2001)